The Pim kinase inhibitor SGI-1776 decreases cell surface expression of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and drug transport by Pim-1-dependent and -independent mechanisms
Karthika Natarajan(Center for Drug Evaluation and Research), Maria R. Baer(University of Maryland, Baltimore), Zhe‐Sheng Chen(New York College of Traditional Chinese Medicine), Mehmet Burcu(Merck & Co., Inc., Rahway, NJ, USA (United States)), Jasjeet Bhullar(University of Maryland, Baltimore), Suneet Shukla(National Cancer Institute), Suresh V. Ambudkar(National Institutes of Health)
Cited by 91
Related Papers
Microbiota in health and diseases
|Signal Transduction and Targeted Therapy|2022|2.9k
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
|The Lancet|2021|795